We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The U.S. Food and Drug Administration (FDA) approved encorafenib (BRAFTOVI, Array BioPharma) in combination with cetuximab for the treatment of adult patients ...
US regulators have issued a green light for Pierre Fabre and Array Biotech’s encorafenib/binimetinib combination therapy for advanced BRAF-mutant melanoma.